712 related articles for article (PubMed ID: 25381721)
1. Blocking and reversing hepatic fibrosis in patients with chronic hepatitis B treated by traditional Chinese medicine (tablets of biejia ruangan or RGT): study protocol for a randomized controlled trial.
Qu J; Yu Z; Li Q; Chen Y; Xiang D; Tan L; Lei C; Bai W; Li H; Shang Q; Chen L; Hu X; Lu W; Li Z; Chen D; Wang X; Zhang C; Xiao G; Qi X; Chen J; Zhou L; Chen G; Li Y; Zeng Z; Rong G; Dong Z; Chen Y; Lou M; Wang C; Lu Y; Zhang C; Yang Y
Trials; 2014 Nov; 15():438. PubMed ID: 25381721
[TBL] [Abstract][Full Text] [Related]
2. Effect of Fufang Biejia Ruangan Tablet on lowering biochemical and virological parameters of hepatic fibrosis in patients with chronic hepatitis B: Protocol for a systematic review and meta-analysis of randomized controlled trials and cohort studies.
Huang C; Shen D; Sun S; Huang Y; Xin Y; Luo H; Chen Y; Zhou Z; Liu F; Chen X
Medicine (Baltimore); 2019 Apr; 98(17):e15297. PubMed ID: 31027094
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of YinQiSanHuang-antiviral decoction in chronic hepatitis B: study protocol for a randomized, placebo-controlled, double-blinded trial.
Wu QJ; Lv WL; Li JM; Zhang TT; Zhou WH; Zhang Q; Wang JC; Wang QN; Zhang RX; Zhao X; Chen ST; Liu S; Li GH; Cao ZM; Xu L; Chen J
Trials; 2020 Jun; 21(1):482. PubMed ID: 32503608
[TBL] [Abstract][Full Text] [Related]
4. Entecavir plus Biejia-Ruangan compound reduces the risk of hepatocellular carcinoma in Chinese patients with chronic hepatitis B.
Ji D; Chen Y; Bi J; Shang Q; Liu H; Wang JB; Tan L; Wang J; Chen Y; Li Q; Long Q; Song L; Jiang L; Xiao G; Yu Z; Chen L; Wang X; Chen D; Li Z; Dong Z; Yang Y
J Hepatol; 2022 Dec; 77(6):1515-1524. PubMed ID: 35985545
[TBL] [Abstract][Full Text] [Related]
5. Synergistic Effect of Biejia-Ruangan on Fibrosis Regression in Patients With Chronic Hepatitis B Treated With Entecavir: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.
Rong G; Chen Y; Yu Z; Li Q; Bi J; Tan L; Xiang D; Shang Q; Lei C; Chen L; Hu X; Wang J; Liu H; Lu W; Chen Y; Dong Z; Bai W; Yoshida EM; Mendez-Sanchez N; Hu KQ; Qi X; Yang Y
J Infect Dis; 2022 Mar; 225(6):1091-1099. PubMed ID: 32437567
[TBL] [Abstract][Full Text] [Related]
6. Chinese Herbal Medicine Combined with Entecavir for HBeAg Positive Chronic Hepatitis B: Study Protocol for a Multi-Center, Double-Blind Randomized-Controlled Trial.
Ye YA; Li XK; Zhou DQ; Chi XL; Li Q; Wang L; Lu BJ; Mao DW; Wu QK; Wang XB; Zhang MX; Xue JD; Li Y; Lu W; Guo JC; Jiang F; Zhang XW; Du HB; Yang XZ; Guo H; Gan DN; Li ZG
Chin J Integr Med; 2018 Sep; 24(9):653-660. PubMed ID: 30209792
[TBL] [Abstract][Full Text] [Related]
7. Chinese herbal formula ruangan granule enhances the efficacy of entecavir to reverse advanced liver fibrosis/early cirrhosis in patients with chronic HBV infection: A multicenter, randomized clinical trial.
Xing Y; Zhong W; Peng D; Han Z; Zeng H; Wang Y; Feng L; Huang J; Xu L; Chen M; Zhou D; Jiang K; Deng X; Zhou H; Tong G
Pharmacol Res; 2023 Apr; 190():106737. PubMed ID: 36940891
[TBL] [Abstract][Full Text] [Related]
8. Chinese herbal medicine combined with entecavir to reduce the off-therapy recurrence risk in HBeAg-positive chronic hepatitis B patients: a multicener, double-blind, randomized controlled trial in China.
Li X; Zhang L; Qiu M; Huang Y; Xiao H; Lu B; Jiang Y; Long F; Lin H; He J; Wu Q; Zhang M; Wang L; Zhu X; Gong M; Sun X; Sun J; Sun F; Lu W; Xu W; Chen G; Li Z; Gan D; Yang X; Du H; Ye Y
Trials; 2020 Aug; 21(1):708. PubMed ID: 32787905
[TBL] [Abstract][Full Text] [Related]
9. Relationship between virological response and FIB-4 index in chronic hepatitis B patients with entecavir therapy.
Li N; Xu JH; Yu M; Wang S; Si CW; Yu YY
World J Gastroenterol; 2015 Nov; 21(43):12421-9. PubMed ID: 26604649
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis B virus long-term impact of antiviral therapy nucleot(s)ide analogues (NUCs).
Grossi G; Viganò M; Loglio A; Lampertico P
Liver Int; 2017 Jan; 37 Suppl 1():45-51. PubMed ID: 28052621
[TBL] [Abstract][Full Text] [Related]
11. Risk of hepatocellular carcinoma in antiviral treatment-naïve chronic hepatitis B patients treated with entecavir or tenofovir disoproxil fumarate: a network meta-analysis.
Huang ZH; Lu GY; Qiu LX; Zhong GH; Huang Y; Yao XM; Liu XH; Huang SJ; Wu T; Yuan Q; Wang YB; Su YY; Zhang J; Xia NS
BMC Cancer; 2022 Mar; 22(1):287. PubMed ID: 35300634
[TBL] [Abstract][Full Text] [Related]
12. Treatment of HBV Cirrhosis with Fuzheng Huayu Tablet () and Entecavir: Design of a Randomized, Double-Blind, Parallel and Multicenter Clinical Trial.
Li ZX; Zhao ZM; Liu P; Zheng QS; Liu CH
Chin J Integr Med; 2021 Jul; 27(7):509-513. PubMed ID: 32572776
[TBL] [Abstract][Full Text] [Related]
13. The efficacy of Chinese patent medicine combined with entecavir for the treatment of chronic HBV-related liver fibrosis or cirrhosis: Protocol for a systematic review and meta-analysis of randomized controlled trials or prospective cohort studies.
Song Y; Zhao J; Wang S; Huang H; Hong J; Zuo J; Huo S
Medicine (Baltimore); 2019 May; 98(22):e15732. PubMed ID: 31145288
[TBL] [Abstract][Full Text] [Related]
14. Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease.
Cho JY; Paik YH; Sohn W; Cho HC; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
Gut; 2014 Dec; 63(12):1943-50. PubMed ID: 24615378
[TBL] [Abstract][Full Text] [Related]
15. Cirrhosis has no impact on therapeutic responses of entecavir for chronic hepatitis B.
Wang PC; Wei TY; Tseng TC; Lin HH; Wang CC
Eur J Gastroenterol Hepatol; 2017 Aug; 29(8):946-950. PubMed ID: 28538267
[TBL] [Abstract][Full Text] [Related]
16. Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients.
Su TH; Hu TH; Chen CY; Huang YH; Chuang WL; Lin CC; Wang CC; Su WW; Chen MY; Peng CY; Chien RN; Huang YW; Wang HY; Lin CL; Yang SS; Chen TM; Mo LR; Hsu SJ; Tseng KC; Hsieh TY; Suk FM; Hu CT; Bair MJ; Liang CC; Lei YC; Tseng TC; Chen CL; Kao JH;
Liver Int; 2016 Dec; 36(12):1755-1764. PubMed ID: 27634134
[TBL] [Abstract][Full Text] [Related]
17. [Entecavir combined with Fufang Biejia Ruangan tablet in treatment of chronic hepatitis B patients with liver fibrosis: 96-week efficacy analyses].
Yang NH; Yuan GS; Zhou YC; Liu JW; Huang HP; Hu CG; Xiong L; Li Y; Zhou FY; Yang SL; Zhou YP
Nan Fang Yi Ke Da Xue Xue Bao; 2016 Jun; 36(6):775-9. PubMed ID: 27320877
[TBL] [Abstract][Full Text] [Related]
18. Changes in APRI and FIB-4 in HBeAg-negative treatment-naive chronic hepatitis B patients with significant liver histological lesions receiving 5-year entecavir therapy.
Liu R; Guo J; Lu Y; Zhang L; Shen G; Wu S; Chang M; Hu L; Hao H; Li M; Xie Y
Clin Exp Med; 2019 Aug; 19(3):309-320. PubMed ID: 31111345
[TBL] [Abstract][Full Text] [Related]
19. Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B.
Papatheodoridis GV; Dalekos GN; Idilman R; Sypsa V; Van Boemmel F; Buti M; Calleja JL; Goulis J; Manolakopoulos S; Loglio A; Papatheodoridi M; Gatselis N; Veelken R; Lopez-Gomez M; Hansen BE; Savvidou S; Kourikou A; Vlachogiannakos J; Galanis K; Yurdaydin C; Esteban R; Janssen HLA; Berg T; Lampertico P
J Hepatol; 2020 Nov; 73(5):1037-1045. PubMed ID: 32553667
[TBL] [Abstract][Full Text] [Related]
20. Long-term outcomes of chronic hepatitis B virus infection in the era of antiviral therapy in Korea.
Park YH; Kim BK; Kim JK; Kim HC; Kim DY; Park JY; Han KH; Kim SU; Shin SH; Hahn KY; Ahn SH
J Gastroenterol Hepatol; 2014 May; 29(5):1005-11. PubMed ID: 24325579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
